{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:24:04Z","timestamp":1761488644599},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T00:00:00Z","timestamp":1299196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11899-011-0085-y","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T20:05:25Z","timestamp":1299269125000},"page":"82-87","source":"Crossref","is-referenced-by-count":14,"title":["In Search of CML Stem Cells\u2019 Deadly Weakness"],"prefix":"10.1007","volume":"6","author":[{"given":"Francesca","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,4]]},"reference":[{"issue":"3","key":"85_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"85_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Cortes JE, O\u2019Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101(1):97\u2013100.","journal-title":"Blood"},{"issue":"24","key":"85_CR3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"85_CR4","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332\u20138.","journal-title":"Blood"},{"issue":"12","key":"85_CR5","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701\u20137.","journal-title":"Blood"},{"key":"85_CR6","first-page":"194","volume":"112","author":"AL Su Chu","year":"2008","unstructured":"Su Chu AL, McDonald T, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5\u00a0years [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:194.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"85_CR7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"\u2022 Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335. This work investigates the possibility of discontinuing IM treatment in patients with a complete molecular remission of at least 2 years\u2019 duration.","journal-title":"Lancet Oncol"},{"key":"85_CR8","first-page":"178","volume":"149","author":"GV Helgason","year":"2010","unstructured":"Helgason GV, Hamilton A, Myssina S, et al. Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)? [abstract] Br J Haematol (BSH Annual Meeting Abstracts). 2010;149:178.","journal-title":"[abstract]. Br J Haematol (BSH Annual Meeting Abstracts)"},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"\u2022\u2022 Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396\u2013409. This paper suggests that primitive CML cells are not oncogene-addicted and that therapies that target BCR-ABL will not eliminate CML stem cells.","journal-title":"J Clin Invest"},{"issue":"2","key":"85_CR10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T Skorski","year":"1995","unstructured":"Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86(2):726\u201336.","journal-title":"Blood"},{"issue":"2","key":"85_CR11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.stem.2007.07.017","volume":"1","author":"Z Tothova","year":"2007","unstructured":"Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell. 2007;1(2):140\u201352.","journal-title":"Cell Stem Cell"},{"issue":"7281","key":"85_CR12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"\u2022\u2022 Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676\u201380. This paper highlights the importance of the FOXO transcription factor family and TGF-\u03b2 in CML development.","journal-title":"Nature"},{"issue":"1","key":"85_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319\u201325.","journal-title":"Blood"},{"issue":"Suppl 1","key":"85_CR14","first-page":"48","volume":"95","author":"F Pellicano","year":"2010","unstructured":"Pellicano F, Helgason GV, Allan E, et al. FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells [abstract]. Haematologica (EHA Annual Meeting Abstract). 2010;95 Suppl 1:48.","journal-title":"Haematologica (EHA Annual Meeting Abstract)"},{"issue":"22","key":"85_CR15","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/MCB.24.22.10058-10071.2004","volume":"24","author":"S Fernan de zdeMattos","year":"2004","unstructured":"Fernandez de Mattos S, Essafi A, Soeiro I, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5\/BCL6-dependent mechanism. Mol Cell Biol. 2004;24(22):10058\u201371.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"85_CR16","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","volume":"278","author":"N Komatsu","year":"2003","unstructured":"Komatsu N, Watanabe T, Uchida M, et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem. 2003;278(8):6411\u201319.","journal-title":"J Biol Chem"},{"issue":"7198","key":"85_CR17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","volume":"453","author":"K Ito","year":"2008","unstructured":"\u2022\u2022 Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453(7198):1072\u20138. This paper highlights the importance of PML in CML development and suggests possible treatments with arsenic-based agents.","journal-title":"Nature"},{"issue":"37","key":"85_CR18","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107(37):16280\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"85_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.dci.2003.09.016","volume":"28","author":"S Subramaniam","year":"2004","unstructured":"Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol. 2004;28(5):415\u201328.","journal-title":"Dev Comp Immunol"},{"issue":"4","key":"85_CR20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOH.0b013e328338c439","volume":"17","author":"JJ Schuringa","year":"2010","unstructured":"Schuringa JJ, Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr Opin Hematol. 2010;17(4):294\u20139.","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"85_CR21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood.V91.4.1216","volume":"91","author":"J Lessard","year":"1998","unstructured":"Lessard J, Baban S, Sauvageau G. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood. 1998;91(4):1216\u201324.","journal-title":"Blood"},{"issue":"20","key":"85_CR22","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1101\/gad.13.20.2691","volume":"13","author":"J Lessard","year":"1999","unstructured":"Lessard J, Schumacher A, Thorsteinsdottir U, et al. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 1999;13(20):2691\u2013703.","journal-title":"Genes Dev"},{"issue":"6937","key":"85_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature01587","volume":"423","author":"IK Park","year":"2003","unstructured":"Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423(6937):302\u20135.","journal-title":"Nature"},{"issue":"7","key":"85_CR24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1101\/gad.8.7.757","volume":"8","author":"NM Lugt van der","year":"1994","unstructured":"van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8(7):757\u201369.","journal-title":"Genes Dev"},{"issue":"6","key":"85_CR25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2004.11.004","volume":"21","author":"A Iwama","year":"2004","unstructured":"Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004;21(6):843\u201351.","journal-title":"Immunity"},{"issue":"5","key":"85_CR26","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2007-08-106666","volume":"111","author":"A Rizo","year":"2008","unstructured":"Rizo A, Dontje B, Vellenga E, et al. Long-term maintenance of human hematopoietic stem\/progenitor cells by expression of BMI1. Blood. 2008;111(5):2621\u201330.","journal-title":"Blood"},{"issue":"1","key":"85_CR27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","volume":"110","author":"M Mohty","year":"2007","unstructured":"Mohty M, Yong AS, Szydlo RM, et al. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 2007;110(1):380\u20133.","journal-title":"Blood"},{"issue":"22","key":"85_CR28","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","volume":"116","author":"A Rizo","year":"2010","unstructured":"Rizo A, Horton SJ, Olthof S, et al. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood. 2010;116(22):4621\u201330.","journal-title":"Blood"},{"issue":"5","key":"85_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0092-8674(91)90382-9","volume":"65","author":"M Lohuizen van","year":"1991","unstructured":"van Lohuizen M, Verbeek S, Scheijen B, et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65(5):737\u201352.","journal-title":"Cell"},{"issue":"17","key":"85_CR30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"85_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1359-6101(96)00047-0","volume":"8","author":"M Sattler","year":"1997","unstructured":"Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR\/ABL. Cytokine Growth Factor Rev. 1997;8(1):63\u201379.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"22","key":"85_CR32","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","volume":"96","author":"X Jiang","year":"1999","unstructured":"Jiang X, Lopez A, Holyoake T, et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 1999;96(22):12804\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"85_CR33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397\u2013409.","journal-title":"Cell"},{"issue":"3","key":"85_CR34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","volume":"93","author":"E Parganas","year":"1998","unstructured":"Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385\u201395.","journal-title":"Cell"},{"issue":"43","key":"85_CR35","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 2001;20(43):6188\u201395.","journal-title":"Oncogene"},{"issue":"47","key":"85_CR36","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21(47):7137\u201346.","journal-title":"Oncogene"},{"issue":"13","key":"85_CR37","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","volume":"66","author":"AK Samanta","year":"2006","unstructured":"Samanta AK, Lin H, Sun T, et al. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468\u201372.","journal-title":"Cancer Res"},{"issue":"14","key":"85_CR38","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","volume":"28","author":"AK Samanta","year":"2009","unstructured":"\u2022 Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28(14):1669\u201381. The authors demonstrate that JAK2 inhibition induces apoptosis in CML cells from patients in all phases, including those that failed IM.","journal-title":"Oncogene"},{"issue":"4","key":"85_CR39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/1947601910372232","volume":"19;1","author":"AK Samanta","year":"2010","unstructured":"Samanta AK, Chakraborty SN, Wang Y, et al. Destabilization of Bcr-Abl\/Jak2 network by a Jak2\/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer. 2010;19;1(4):346\u201359.","journal-title":"Genes Cancer"},{"issue":"4","key":"85_CR40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/path.2669","volume":"220","author":"A Hamilton","year":"2010","unstructured":"Hamilton A, Gallipoli P, Nicholson E, Holyoake TL. Targeted therapy in haematological malignancies. J Pathol. 2010;220(4):404\u201318.","journal-title":"J Pathol"},{"issue":"4","key":"85_CR41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2008.02.001","volume":"14","author":"J Westermarck","year":"2008","unstructured":"Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14(4):152\u201360.","journal-title":"Trends Mol Med"},{"issue":"5","key":"85_CR42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355\u201368.","journal-title":"Cancer Cell"},{"issue":"9","key":"85_CR43","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","volume":"117","author":"P Neviani","year":"2007","unstructured":"Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408\u201321.","journal-title":"J Clin Invest"},{"key":"85_CR44","first-page":"189","volume":"112","author":"P Neviani","year":"2008","unstructured":"Neviani P, Santhanam R, Ma Y, et al. Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph+ chronic myelogenous leukemia (CML) CD34+\/CD38- stem cell through the simultaneous suppression of BCR\/ABL and BCR\/ABL-independent signals [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:189.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"85_CR45","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1182\/blood-2006-01-030015","volume":"108","author":"RA Shivdasani","year":"2006","unstructured":"Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006;108(12):3646\u201353.","journal-title":"Blood"},{"issue":"5","key":"85_CR46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","volume":"140","author":"AM Eiring","year":"2010","unstructured":"\u2022 Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652\u201365. This paper describes for the first time the dual activity of miR-328 in controlling cell fate through association with mRNA targets and through its decoy role.","journal-title":"Cell"},{"issue":"5654","key":"85_CR47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1126\/science.1091903","volume":"303","author":"CZ Chen","year":"2004","unstructured":"Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83\u20136.","journal-title":"Science"},{"issue":"10","key":"85_CR48","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399\u2013405.","journal-title":"Blood"},{"issue":"6","key":"85_CR49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496\u2013506.","journal-title":"Cancer Cell"},{"issue":"9","key":"85_CR50","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109(9):4016\u201319.","journal-title":"Blood"},{"issue":"11","key":"85_CR51","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532\u20139.","journal-title":"Blood"},{"key":"85_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","volume":"25","author":"DM Ross","year":"2011","unstructured":"Ross DM, Hughes T, Melo JV. Do we have to kill the last CML cell? Leukemia. 2011;25:193\u2013200.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0085-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0085-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T20:41:28Z","timestamp":1637354488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0085-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0085-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,4]]}}}